Adjuvant Transarterial chemoembolization does not influence recurrence-free or overall survival in patients with combined hepatocellular carcinoma and Cholangiocarcinoma after curative resection: a propensity score matching analysis
Abstract Background The prognosis of patients with combined hepatocellular carcinoma and intrahepatic cholangiocarcinoma (CHC) is usually poor, and effective adjuvant therapy is missing making it important to investigate whether these patients may benefit from adjuvant transarterial chemoembolizatio...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2020-07-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12885-020-07138-z |
| _version_ | 1819088022804627456 |
|---|---|
| author | Wei-Ren Liu Meng-Xin Tian Chen-Yang Tao Zheng Tang Yu-Fu Zhou Shu-Shu Song Xi-Fei Jiang Han Wang Pei-Yun Zhou Wei-Feng Qu Yuan Fang Zhen-Bin Ding Jian Zhou Jia Fan Ying-Hong Shi |
| author_facet | Wei-Ren Liu Meng-Xin Tian Chen-Yang Tao Zheng Tang Yu-Fu Zhou Shu-Shu Song Xi-Fei Jiang Han Wang Pei-Yun Zhou Wei-Feng Qu Yuan Fang Zhen-Bin Ding Jian Zhou Jia Fan Ying-Hong Shi |
| author_sort | Wei-Ren Liu |
| collection | DOAJ |
| description | Abstract Background The prognosis of patients with combined hepatocellular carcinoma and intrahepatic cholangiocarcinoma (CHC) is usually poor, and effective adjuvant therapy is missing making it important to investigate whether these patients may benefit from adjuvant transarterial chemoembolization (TACE). We aimed to evaluate the efficiency of adjuvant TACE for long-term recurrence and survival after curative resection before and after propensity score matching (PSM) analysis. Methods In this retrospective study, of 230 patients who underwent resection for CHC between January 1994 and December 2014, 46 (18.0%) patients received adjuvant TACE. Univariate and multivariate regression analyses were used to identify the independent predictive factors of survival. Cox regression analyses and log-rank tests were used to compare overall survival (OS) and disease-free survival (DFS) between patients who did or did not receive adjuvant TACE. Results A total of 230 patients (mean age 52.2 ± 11.9 years; 172 men) were enrolled, and 46 (mean age 52.7 ± 11.1 years; 38 men) patients received TACE. Before PSM, in multivariate regression analysis, γ-glutamyl transpeptidase (γ-GT), tumour nodularity, macrovascular invasion (MVI), lymphoid metastasis, and extrahepatic metastasis were associated with OS. Alanine aminotransferase (ALT), MVI, lymphoid metastasis, and preventive TACE (HR: 2.763, 95% CI: 1.769–4.314, p < 0.001) were independent prognostic factors for DFS. PSM created 46 pairs of patients. Before PSM, adjuvant preventive TACE was not associated with an increased risk of OS (HR: 0.911, 95% CI: 0.545–1.520, p = 0.720) or DFS (HR: 3.345, 95% CI: 1.686–6.638, p = 0.001). After PSM, the 5-year OS and DFS rates were comparable in the TACE group and the non-TACE group (OS: 22.7% vs 14.9%, respectively, p = 0.75; DFS: 11.2% vs 14.4%, respectively, p = 0.06). Conclusions The present study identified that adjuvant preventive TACE did not influence DFS or OS after curative resection of CHC. |
| first_indexed | 2024-12-21T21:45:26Z |
| format | Article |
| id | doaj.art-debbe9cf40944b86b3ce793ee2e701ea |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-12-21T21:45:26Z |
| publishDate | 2020-07-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-debbe9cf40944b86b3ce793ee2e701ea2022-12-21T18:49:15ZengBMCBMC Cancer1471-24072020-07-0120111110.1186/s12885-020-07138-zAdjuvant Transarterial chemoembolization does not influence recurrence-free or overall survival in patients with combined hepatocellular carcinoma and Cholangiocarcinoma after curative resection: a propensity score matching analysisWei-Ren Liu0Meng-Xin Tian1Chen-Yang Tao2Zheng Tang3Yu-Fu Zhou4Shu-Shu Song5Xi-Fei Jiang6Han Wang7Pei-Yun Zhou8Wei-Feng Qu9Yuan Fang10Zhen-Bin Ding11Jian Zhou12Jia Fan13Ying-Hong Shi14Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan UniversityDepartment of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan UniversityDepartment of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan UniversityDepartment of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan UniversityDepartment of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan UniversityDepartment of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan UniversityDepartment of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan UniversityDepartment of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan UniversityDepartment of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan UniversityDepartment of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan UniversityDepartment of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan UniversityDepartment of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan UniversityDepartment of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan UniversityDepartment of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan UniversityDepartment of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan UniversityAbstract Background The prognosis of patients with combined hepatocellular carcinoma and intrahepatic cholangiocarcinoma (CHC) is usually poor, and effective adjuvant therapy is missing making it important to investigate whether these patients may benefit from adjuvant transarterial chemoembolization (TACE). We aimed to evaluate the efficiency of adjuvant TACE for long-term recurrence and survival after curative resection before and after propensity score matching (PSM) analysis. Methods In this retrospective study, of 230 patients who underwent resection for CHC between January 1994 and December 2014, 46 (18.0%) patients received adjuvant TACE. Univariate and multivariate regression analyses were used to identify the independent predictive factors of survival. Cox regression analyses and log-rank tests were used to compare overall survival (OS) and disease-free survival (DFS) between patients who did or did not receive adjuvant TACE. Results A total of 230 patients (mean age 52.2 ± 11.9 years; 172 men) were enrolled, and 46 (mean age 52.7 ± 11.1 years; 38 men) patients received TACE. Before PSM, in multivariate regression analysis, γ-glutamyl transpeptidase (γ-GT), tumour nodularity, macrovascular invasion (MVI), lymphoid metastasis, and extrahepatic metastasis were associated with OS. Alanine aminotransferase (ALT), MVI, lymphoid metastasis, and preventive TACE (HR: 2.763, 95% CI: 1.769–4.314, p < 0.001) were independent prognostic factors for DFS. PSM created 46 pairs of patients. Before PSM, adjuvant preventive TACE was not associated with an increased risk of OS (HR: 0.911, 95% CI: 0.545–1.520, p = 0.720) or DFS (HR: 3.345, 95% CI: 1.686–6.638, p = 0.001). After PSM, the 5-year OS and DFS rates were comparable in the TACE group and the non-TACE group (OS: 22.7% vs 14.9%, respectively, p = 0.75; DFS: 11.2% vs 14.4%, respectively, p = 0.06). Conclusions The present study identified that adjuvant preventive TACE did not influence DFS or OS after curative resection of CHC.http://link.springer.com/article/10.1186/s12885-020-07138-zCombined hepatocellular carcinoma and intrahepatic cholangiocarcinomaTransarterial chemoembolizationOverall survivalDisease-free survivalPropensity score matching analysis |
| spellingShingle | Wei-Ren Liu Meng-Xin Tian Chen-Yang Tao Zheng Tang Yu-Fu Zhou Shu-Shu Song Xi-Fei Jiang Han Wang Pei-Yun Zhou Wei-Feng Qu Yuan Fang Zhen-Bin Ding Jian Zhou Jia Fan Ying-Hong Shi Adjuvant Transarterial chemoembolization does not influence recurrence-free or overall survival in patients with combined hepatocellular carcinoma and Cholangiocarcinoma after curative resection: a propensity score matching analysis BMC Cancer Combined hepatocellular carcinoma and intrahepatic cholangiocarcinoma Transarterial chemoembolization Overall survival Disease-free survival Propensity score matching analysis |
| title | Adjuvant Transarterial chemoembolization does not influence recurrence-free or overall survival in patients with combined hepatocellular carcinoma and Cholangiocarcinoma after curative resection: a propensity score matching analysis |
| title_full | Adjuvant Transarterial chemoembolization does not influence recurrence-free or overall survival in patients with combined hepatocellular carcinoma and Cholangiocarcinoma after curative resection: a propensity score matching analysis |
| title_fullStr | Adjuvant Transarterial chemoembolization does not influence recurrence-free or overall survival in patients with combined hepatocellular carcinoma and Cholangiocarcinoma after curative resection: a propensity score matching analysis |
| title_full_unstemmed | Adjuvant Transarterial chemoembolization does not influence recurrence-free or overall survival in patients with combined hepatocellular carcinoma and Cholangiocarcinoma after curative resection: a propensity score matching analysis |
| title_short | Adjuvant Transarterial chemoembolization does not influence recurrence-free or overall survival in patients with combined hepatocellular carcinoma and Cholangiocarcinoma after curative resection: a propensity score matching analysis |
| title_sort | adjuvant transarterial chemoembolization does not influence recurrence free or overall survival in patients with combined hepatocellular carcinoma and cholangiocarcinoma after curative resection a propensity score matching analysis |
| topic | Combined hepatocellular carcinoma and intrahepatic cholangiocarcinoma Transarterial chemoembolization Overall survival Disease-free survival Propensity score matching analysis |
| url | http://link.springer.com/article/10.1186/s12885-020-07138-z |
| work_keys_str_mv | AT weirenliu adjuvanttransarterialchemoembolizationdoesnotinfluencerecurrencefreeoroverallsurvivalinpatientswithcombinedhepatocellularcarcinomaandcholangiocarcinomaaftercurativeresectionapropensityscorematchinganalysis AT mengxintian adjuvanttransarterialchemoembolizationdoesnotinfluencerecurrencefreeoroverallsurvivalinpatientswithcombinedhepatocellularcarcinomaandcholangiocarcinomaaftercurativeresectionapropensityscorematchinganalysis AT chenyangtao adjuvanttransarterialchemoembolizationdoesnotinfluencerecurrencefreeoroverallsurvivalinpatientswithcombinedhepatocellularcarcinomaandcholangiocarcinomaaftercurativeresectionapropensityscorematchinganalysis AT zhengtang adjuvanttransarterialchemoembolizationdoesnotinfluencerecurrencefreeoroverallsurvivalinpatientswithcombinedhepatocellularcarcinomaandcholangiocarcinomaaftercurativeresectionapropensityscorematchinganalysis AT yufuzhou adjuvanttransarterialchemoembolizationdoesnotinfluencerecurrencefreeoroverallsurvivalinpatientswithcombinedhepatocellularcarcinomaandcholangiocarcinomaaftercurativeresectionapropensityscorematchinganalysis AT shushusong adjuvanttransarterialchemoembolizationdoesnotinfluencerecurrencefreeoroverallsurvivalinpatientswithcombinedhepatocellularcarcinomaandcholangiocarcinomaaftercurativeresectionapropensityscorematchinganalysis AT xifeijiang adjuvanttransarterialchemoembolizationdoesnotinfluencerecurrencefreeoroverallsurvivalinpatientswithcombinedhepatocellularcarcinomaandcholangiocarcinomaaftercurativeresectionapropensityscorematchinganalysis AT hanwang adjuvanttransarterialchemoembolizationdoesnotinfluencerecurrencefreeoroverallsurvivalinpatientswithcombinedhepatocellularcarcinomaandcholangiocarcinomaaftercurativeresectionapropensityscorematchinganalysis AT peiyunzhou adjuvanttransarterialchemoembolizationdoesnotinfluencerecurrencefreeoroverallsurvivalinpatientswithcombinedhepatocellularcarcinomaandcholangiocarcinomaaftercurativeresectionapropensityscorematchinganalysis AT weifengqu adjuvanttransarterialchemoembolizationdoesnotinfluencerecurrencefreeoroverallsurvivalinpatientswithcombinedhepatocellularcarcinomaandcholangiocarcinomaaftercurativeresectionapropensityscorematchinganalysis AT yuanfang adjuvanttransarterialchemoembolizationdoesnotinfluencerecurrencefreeoroverallsurvivalinpatientswithcombinedhepatocellularcarcinomaandcholangiocarcinomaaftercurativeresectionapropensityscorematchinganalysis AT zhenbinding adjuvanttransarterialchemoembolizationdoesnotinfluencerecurrencefreeoroverallsurvivalinpatientswithcombinedhepatocellularcarcinomaandcholangiocarcinomaaftercurativeresectionapropensityscorematchinganalysis AT jianzhou adjuvanttransarterialchemoembolizationdoesnotinfluencerecurrencefreeoroverallsurvivalinpatientswithcombinedhepatocellularcarcinomaandcholangiocarcinomaaftercurativeresectionapropensityscorematchinganalysis AT jiafan adjuvanttransarterialchemoembolizationdoesnotinfluencerecurrencefreeoroverallsurvivalinpatientswithcombinedhepatocellularcarcinomaandcholangiocarcinomaaftercurativeresectionapropensityscorematchinganalysis AT yinghongshi adjuvanttransarterialchemoembolizationdoesnotinfluencerecurrencefreeoroverallsurvivalinpatientswithcombinedhepatocellularcarcinomaandcholangiocarcinomaaftercurativeresectionapropensityscorematchinganalysis |